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Primary del 17 chronic lymphocytic leukaemia lymphocytes are
hypersensitive to dasatinib in vitro
Chronic lymphocytic leukaemia (CLL) is characterized by the
accumulation of mature quiescent B-lymphocytes in the G0/G1
phaseofthecellcycle.B-lymphocyteaccumulationislikelytobe
a consequence of an undeﬁned defect in the apoptotic machin-
ery rather than an increased proliferation of leukaemic cells
(Hamblin & Oscier, 1997). The prolonged survival of CLL
lymphocyteshasalsobeenlinkedtoderegulatedexpressionand/
or activity of related non receptor tyrosine kinases including
members of the SRC family kinases (SFK) and ABL1. Inhibition
of either c-abl (Aloyz et al, 2004) or SFK (Contri et al, 2005)
results in CLL lymphocyte death in vitro. Previous results from
our laboratory suggest that dasatinib cytotoxicity in CLL
lymphocytes is associated with c-abl rather than SFK inhibition
(Amrein et al, 2008a). Recent results of phase I–II clinical trials
using dasatinib in CLL suggest that the drug might be beneﬁcial
in only a small subset (£10%) of previously treated patients
(Amrein et al, 2008b). In agreement with these clinical results,
we have recently reported that dasatinib is cytotoxic to primary
CLL lymphocytes in vitro but mainly at clinically unobtainable
concentrations (Amrein et al, 2008a). Although dasatinib
resistance was associated with the basal expression of c-abl,
our study suggested that wild type TP53 is important in CLL
lymphocyte homeostasis and/or survival in the presence of
dasatinib (Amrein et al, 2008a). To test this hypothesis we
assessed: (i) dasatinib cytotoxicity in p53 proﬁcient (wild type)
CLL lymphocytes treated with dasatinib in the presence or
absence of piﬁthrin-a, a small molecule inhibitor of p53
transcriptional activity (Steele et al, 2008) and 2) dasatinib
cytotoxicity in primary CLL lymphocytes with impaired TP53
signalling from patients diagnosed with del 17p13.1. In the
eleven samples we veriﬁed the functionality of p53 signalling as
described before by examining changes in p53 and its down-
stream target p21Cip1 (p21) after treatment with chlorambucil
(Willmore et al, 2008). Brieﬂy, the lymphocytes were treated
with equivalent cytotoxic concentrations of chlorambucil (50%
inhibitory concentrations [IC50’s]) for 24 h and induced p53
and p21 protein levels were monitored by Western blotting. As
expected p53 and p21 protein levels were induced by chloram-
bucilonlyinTP53wildtypeCLLlymphocytes(datanotshown).
As previously reported, dasatinib IC50s in vitro in CLL
lymphocytes expressing wild type TP53 were not in the
clinically attainable range (mean value of 30 lmol/l, Table I)
(Amrein et al, 2008a). In contrast, the dasatinib IC50s in del
17p13.1 lymphocytes were signiﬁcantly lower (up to 100 times)
than in the wild type TP53 lymphocytes. Moreover, in
agreement with previous reports demonstrating that del
17p13.1 is associated with chemoresistance in CLL lympho-
cytes, we found that del 17p13.1 lymphocytes were signiﬁcantly
more resistant to chlorambucil that TP53 wild type CLL
lymphocytes [Table I, Fig 1A (Zenz et al, 2008)].
In available wild type TP53 CLL samples, piﬁthrin-a
sensitized the lymphocytes of 2 out 3 patients (1Æ3 and 12-fold)
(Table I). Importantly, piﬁthrin-a was not toxic to CLL
lymphocytes when used alone. Treatment with dasatinib for
twenty four hours resulted in a dose dependent reduction of
p53 and p21 basal expression levels in the lymphocytes of
Table I. Clinical characteristic of the patients and IC50 concentrations
of dasatinib and chlorambucil in primary CLL-lymphocytes in vitro.
Patient
Deletion 17
Deletion 11
RAI
stage
Previous
treatment
Dasatinib
(lmol/l)
CLB
(lmol/l)
1 Negative I CLB 0Æ81 7 Æ3
2 Negative 0 FLU 30Æ6( 2 Æ4) 23Æ0
3 N.D. III CLB 7Æ23 0 Æ0
4 Negative 0 No 0Æ14 1 Æ0
5 Negative 0 No 36Æ0 (27Æ0) 18Æ6
6 N.D. III CLB 28Æ21 0 Æ9
7 Negative II CLB 40Æ0 (40Æ0) 24Æ9
8 Del 17p13.1 (86%)
Del 11q22–23 (N.D.)
II CLB 0Æ27 36Æ7
9 Del 17p13.1 (94%)
Del 11q22–23 (5%)
I CLB/FLU/
Rituximab
0Æ01 44Æ7
10 Del 17p13.1 (79%)
Del 1q22–231 (76%)
IN o 0 Æ01 100
11 Del 17p13.1 (33%)
Del 11q22–23 (10%)
II CLB 0Æ17 100
Primary CLL lymphocytes, isolated and plated as described above, were
incubated in the presence of dasatinib or chlorambucil (CLB). The IC50
concentrations are expressed in lmol/l and determined after 72 h
incubation in vitro using the MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-Diphenyltetrazolium Bromide) assay as described (Amrein et al,
2008a). The numbers in parentheses indicate the dasatinib IC50 in the
presence of 25 lmol/l piﬁthrin-a. The percentage of lymphocytes with
del 17 and del 11 in each samples are indicated. Samples displaying
percentages above 4Æ8% and 6Æ6% for del 17 and del 11 respectively
were considered positive.
Negative percentage lower than the cut-off point.
N.D. not determined; CLB, chlorambucil.
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Fig 1. Dasatinib decreases p53 basal expression levels in primary CLL lymphocytes expressing wild type p53. Dasatinib and chlorambucil IC50s were
signiﬁcantly different between CLL lymphocytes expressing wild type TP53 or del 17 (*P = 0.012). The bars represent the median values and 95%
conﬁdence intervals (CI 95%). (A). The lymphocytes of 11 CLL lymphocyte patients were treated for 24 h with vehicle (dimethyl sulphoxide),
dasatinib 100 nmol/l or the IC50 concentration as shown in Table I. Protein extracts were obtained as described before and 50 lg of proteins for each
sample were resolved by sodium dodecyl sulphate poyacrylamide gel electrophoresis. p53 and p21 protein levels were assessed by Western blot using
speciﬁc antibodies (Amrein et al, 2008a). The signals obtained in TP53 wild type lymphocytes (B) were analysed using National Institutes of Health -
Scion image and normalized to actin, p53 or p21 levels (y-axis) and are expressed as the percentage of vehicle treated lymphocytes (control) value
([OD value/control OD value]x 100) vis a ` vis the treatments indicated in the x-axis; * and ** indicates signiﬁcance P =0 Æ003 and P =0 Æ004
respectively (C). Dasatinib-induced changes in p53 levels and p21 signal were not detected in protein extracts from del 17p13Æ1 CLL lymphocytes
(D). Dasatinib IC50s correlate with the percentage of residual p53 protein levels (in respect to vehicle treated lymphocytes) after dasatinib treatment,
r =0 Æ82, P =0 Æ02 (E). Two-sided tests with a-value of 0Æ05 were used. Correlations between the data were assessed using the Spearman test. All tests
were performed using SigmaStat software.
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levels were not affected in del 17 lymphocytes. Importantly, p21
was not detected in del 17p13.1 lymphocytes suggesting that
TP53 is not functional (Fig 1D). These results are in agreement
with previous reports suggesting that in the majority of CLL
patients with malignant lymphocytes displaying del 17p13.1,
the remaining TP53 allele is mutated (Zenz et al, 2008).
In addition, we found that dasatinib resistance (higher IC50)
in CLL lymphocytes expressing wild type TP53 correlated with
residual p53 protein levels (in respect to control) after
dasatinib treatment (r =0 Æ8, P =0 Æ02, Fig 1E). As ATM is a
key regulator of p53 functionality, we assessed del 11q22-23
status in del 17p13.1 lymphocytes (Table I) (Pettitt et al,
2001). Two of the three del 17p13.1 samples tested were
positive for del 11q22–23. Although del 17p13.1 lymphocytes
were hypersensitive when compared to p53 proﬁcient lym-
phocytes, we did not ﬁnd a correlation between the percentage
of del 17p13.1 or del 11q22–23 in the lymphocytes and the IC50
of dasatinib. Studies regarding the role of p53 signalling (and
its regulators e.g. ATM) in dasatinib sensitivity in a larger
cohort of CLL samples should be informative.
Taken together, our results suggest that p53 is important to
maintain CLL lymphocyte homeostasis following exposure to
dasatinib and suggest that dasatinib may be effective to treat del
17p13.1 CLL patients. The recent report of an excellent clinical
response to dasatinib of a CLL patient with lymphocytes
displayingdel17p13.1supportsthishypothesis(Pitiniet al,2009).
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MicroRNA expression in chronic lymphocytic leukaemia
B-cell chronic lymphocytic leukaemia (B-CLL) is the most
common adult leukaemia in the Western world and is
characterized by the accumulation of CD5
+/CD19
+/CD23
+
mature B cells. The molecular pathology of the disease however
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